Empirical Antibiotic Management for Community-Acquired Pneumonia
For outpatient CAP without comorbidities, use amoxicillin 1g three times daily as first-line therapy; for outpatients with comorbidities, use combination therapy with amoxicillin/clavulanate plus a macrolide or respiratory fluoroquinolone monotherapy; for non-ICU inpatients, use a beta-lactam plus macrolide or respiratory fluoroquinolone; and for ICU patients, use a beta-lactam plus either azithromycin or a respiratory fluoroquinolone. 1
Outpatient Management
Healthy Adults Without Comorbidities
The 2019 ATS/IDSA guidelines provide clear first-line options 1:
- Amoxicillin 1g three times daily (strong recommendation, moderate quality evidence)
- Doxycycline 100mg twice daily (conditional recommendation, low quality evidence)
- Macrolide monotherapy (azithromycin 500mg day 1, then 250mg daily OR clarithromycin 500mg twice daily) - ONLY if local pneumococcal macrolide resistance is <25% (conditional recommendation)
Critical caveat: The 2026 ATS update notes that macrolides alone are NOT considered adequate treatment for outpatients in the United States due to high rates of macrolide-resistant Streptococcus pneumoniae 2. This makes amoxicillin the preferred first-line agent.
Outpatients With Comorbidities
For patients with chronic heart, lung, liver, or renal disease; diabetes; alcoholism; malignancy; or asplenia 1:
Combination Therapy (Preferred):
- Beta-lactam: amoxicillin/clavulanate (500/125mg three times daily OR 875/125mg twice daily OR 2000/125mg twice daily) OR cephalosporin (cefpodoxime 200mg twice daily OR cefuroxime 500mg twice daily)
- PLUS macrolide (azithromycin 500mg day 1, then 250mg daily OR clarithromycin 500mg twice daily) (strong recommendation)
- OR doxycycline 100mg twice daily instead of macrolide (conditional recommendation)
Monotherapy Alternative:
- Respiratory fluoroquinolone: levofloxacin 750mg daily OR moxifloxacin 400mg daily OR gemifloxacin 320mg daily (strong recommendation)
Non-ICU Inpatient Management
For hospitalized patients with non-severe CAP 1:
Recommended Regimens:
- Beta-lactam plus macrolide (strong recommendation)
- Respiratory fluoroquinolone monotherapy (strong recommendation)
The 2024 retrospective study confirmed no significant differences in mortality or clinical outcomes among fluoroquinolone monotherapy, macrolide plus beta-lactam, or doxycycline plus beta-lactam regimens 3. This supports guideline flexibility, though the strongest evidence supports the first two options.
ICU/Severe CAP Management
For patients with severe CAP requiring ICU admission 1:
Standard Severe CAP:
- Beta-lactam (third-generation cephalosporin) PLUS macrolide (azithromycin preferred)
- OR Beta-lactam PLUS respiratory fluoroquinolone
With Pseudomonas Risk Factors:
- Antipseudomonal beta-lactam (piperacillin/tazobactam, imipenem/cilastatin, meropenem, doripenem, or cefepime)
- PLUS aminoglycoside
- PLUS azithromycin OR antipseudomonal fluoroquinolone (levofloxacin or ciprofloxacin)
With MRSA Risk Factors:
- Add vancomycin OR linezolid
- Ceftaroline for resistant cases
Duration of Therapy
The 2026 ATS guidelines represent a significant shift toward shorter durations 2, 4, 5:
For Outpatients and Non-Severe Inpatients:
- Minimum 3 days if clinical stability achieved by day 3 (conditional recommendation)
- Continue to 5 days if stability achieved by day 5
- Maximum 7 days for uncomplicated cases
Clinical Stability Criteria (ALL must be met):
- Temperature <37.8°C
- Heart rate <100 bpm
- Respiratory rate <24 breaths/min
- SpO₂ >90% on room air (or baseline oxygen requirement)
- Systolic BP >90 mmHg
- Normal mental status
For Severe CAP/ICU Patients:
- 5 days or greater (strong recommendation) 2
- Higher risk of disseminated infection and treatment failure necessitates longer courses
Important considerations: Account for antibiotic pharmacokinetics—macrolides have a 3-day half-life, so 3 days of azithromycin provides extended coverage 2. Adjust for renal/hepatic function. Over 50% of hospitalized patients may not meet criteria for short courses due to comorbidities 2.
Critical Pitfalls to Avoid
- Do NOT use macrolide monotherapy in U.S. outpatients due to resistance patterns 2
- Do NOT use fluoroquinolone doses lower than recommended: 750mg levofloxacin or 400mg moxifloxacin for CAP 2
- Do NOT prescribe fixed antibiotic durations at presentation—assess daily for clinical stability 2
- Do NOT use short-course antibiotics in severe CAP—these patients were excluded from trials 2
- Ensure close follow-up when prescribing 3-day courses, with clear plans for monitoring recurrence 2
- Switch to oral therapy within 72 hours once clinically stable and able to tolerate oral medications 1